Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom
ConclusionUse of CT-P13 SC may lead to substantial cost savings for the UK society.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
More News: Arthritis | Economics | Epidemiology | European Medicines Agency (EMA) | Health Management | Remicade | Rheumatoid Arthritis | Rheumatology | UK Health